3Ribera JM. Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia : how to best use all the available tools [ J ]. Leuk Lymphoma ,2013,54 ( 1 ) :21 - 27.
4Fielding AK. How I trent Philadelphia chromosome- positive acute lymphoblastic lenkemia [ J ]. Blood,2010, 116(18) :3409 -3417.
5Ohno R. Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastie leukemia [ J]. Curr Hematol Malig Rep,2010,5 (4) :213 -221.
7Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper- CVAD ), a dose-intensive regimen, in adult acute lymphocytic leukemia [ J].Cancer,2004,101 ( 12 ) :2788 - 2801.
8Esperou H, Boiron JM, Cayuela JM, et al. A potential graftversus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia:result from the French Bone Marrow Transplantation Society [ J ]. Bone Marrow Transplant, 2003,31 ( 10 ) : 909 - 918.
9Yanada M, Naoe T, Iida H, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease [ J ]. Bone Marrow Transplant,2005,36(10) :867 - 872.
10Yoshimura T, Nakane T, Hirose A, et al. Prognostic factora and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) pre-treated with tyrosine kinase inhibitors [ J ]. Osaka City Med, 2013,59(1) :9 -21.
二级参考文献75
1Quintas -Cardama A, Cortes J. Molecular biology of bcr-abll -positivechronic myeloid leukemia[J]. Blood ,2009,113: 1619-1630.
2Melo JV. The diversity of Bcr-Abl fusion proteins and the relationship toleukemia phenotype[J]. Blood, 1996,88 : 2375-2384.
3Thielen N , Ossenkoppele GJ,Schuurhuis GJ,et al. New insights into thepathogenesis of chronic myeloid leukaemia : towards a path to cure [J].Neth J Med,2011,69(10);430-440.
4Jatiani SS, Cosenza SC , Reddy MV,et al. A non-ATP-competitive dualinhibitor of JAK2 and BCR-ABL kinases:elucidation of a novel therapeutic spectrum based on substrate competitive inhibition[J]. Genes Can-cer,2010,1 :331-345.
5O Brien SG,Guilhot F,Goldman JM,et al. International randomizedstudy of interferon versus STI571. (IRIS) 7-year follow—up:survival,low rate of transformation and increased rate of major molecular response(MMR) in patients(pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [J]. Blood, 2008,112 : 186.
6Thomas J,Wang L,Clark RE,et al. Active transport of imatinib intoand out of cell implications for drug resistance[J]. Blood ,2004,104 :3739-3745.
7Chomel JC ,Turhan AG. Chronic myeloid leukemia stem cells in the eraof targeted therapies : resistance, persistence and long-term dormancy[J].Oncotarget ,2011,2(9) :713-727.
8KantarjianHM,GilesF,Gattermann N,et aL Nilotinib(formerly AMN107),a highly selective BCR-ABL tyrosine kinase inhibitor, is effective inpatients with Philadelphia chromosome -positive chronic myelogenousleukemia in chronic phase following imatinib resistance and intoler-ance[J]. Blood,2007,110:3540-3546.
9Rix U,Hantschel O,Dumberger G,et al. Chemical proteomic profilesof the BCR -ABL inhibitors imatinib, nilotinib, and dasatinib revealnovel kinase and nonkinase targets[J]. Blood,2007,110:4055-4063.
10Burmeister T, Schwartz S,Bartram CR,et al. Patients' ageand BCR-ABL frequency in adult retrospective analysisfrom the GM ALL study group [ J] . Blood,2008 ,112(3):918 -919.
